Beat The Denominator

The recent drop in Hims & Hers Health (HIMS) stock is considered a significant buying opportunity due to a market overreaction. Wall Street has misjudged the termination of the Novo Nordisk (NVO) partnership, as the affected GLP-1 business only accounts for 15-20% of total revenue. The core investment thesis is that HIMS is a disruptive telehealth platform with a strong, customer-centric model for personalized care. A potential future catalyst for the stock could be a new weight-loss drug partnership with Eli Lilly (LLY). Investors should focus on the company's long-term potential to disrupt the primary care market, not just the short-term weight loss narrative.